Analytical Data
-
Gene name
rhlR
- Application
-
Alternative Names
Elastase modulator
-
Species
Pseudomonas aeruginosa
-
Source
E. coli
-
Tag
N- His-SUMO & C- Myc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P54292
-
Expression Region
1-241aa
-
Molecular Weight
47.6 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Research on the rhlR recombinant protein has gained significant attention due to its critical role in the regulation of virulence factors in the opportunistic pathogen Pseudomonas aeruginosa. This bacteria is known for its ability to cause infections in immunocompromised individuals and its resistance to multiple antibiotics. The rhlR gene encodes a transcriptional regulator involved in the synthesis of rhamnolipids, which are biosurfactants that contribute to the bacteria's biofilm formation, motility, and virulence. Understanding the function of rhlR is essential for developing new therapeutic strategies to combat P. aeruginosa infections, particularly in hospital settings where multidrug-resistant strains are prevalent. Studies on the recombinant form of rhlR facilitate the elucidation of its interactions with other signaling molecules and genes within the quorum sensing system, a critical communication process that enables bacterial populations to coordinate their behavior and establish infections. By producing and characterizing rhlR as a recombinant protein, researchers aim to uncover its structural, biochemical, and functional properties, shedding light on its potential as a target for novel antimicrobial therapies. This research not only contributes to fundamental microbiology but also holds promise for clinical applications in managing Pseudomonas aeruginosa infections, which pose significant challenges in healthcare.
